Neumora Therapeutics (NASDAQ:NMRA) Now Covered by Analysts at Leerink Partners

Leerink Partners started coverage on shares of Neumora Therapeutics (NASDAQ:NMRA) in a report released on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $8.00 target price on the stock.

NMRA has been the topic of several other reports. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. Needham & Company LLC lifted their price target on Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Tuesday, September 16th. Finally, Stifel Nicolaus lifted their target price on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, Neumora Therapeutics has an average rating of “Hold” and an average price target of $8.13.

Neumora Therapeutics Price Performance

NMRA stock opened at $2.22 on Monday. The company has a 50 day moving average of $2.19 and a two-hundred day moving average of $1.89. The company has a market cap of $370.94 million, a price-to-earnings ratio of -1.51 and a beta of 3.22. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.25. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, equities analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kristina Burow acquired 1,915,700 shares of Neumora Therapeutics stock in a transaction dated Monday, October 27th. The stock was acquired at an average cost of $2.61 per share, for a total transaction of $4,999,977.00. Following the completion of the purchase, the director owned 6,046,907 shares of the company’s stock, valued at $15,782,427.27. This represents a 46.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Arch Venture Partners Xii, Llc acquired 1,915,700 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were purchased at an average cost of $2.61 per share, with a total value of $4,999,977.00. Following the completion of the acquisition, the insider owned 6,046,907 shares in the company, valued at $15,782,427.27. This trade represents a 46.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in Neumora Therapeutics by 151.1% during the first quarter. Invesco Ltd. now owns 123,655 shares of the company’s stock valued at $124,000 after acquiring an additional 74,406 shares during the period. AQR Capital Management LLC acquired a new position in shares of Neumora Therapeutics during the 1st quarter worth about $463,000. Vanguard Personalized Indexing Management LLC boosted its stake in Neumora Therapeutics by 130.3% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 58,196 shares of the company’s stock valued at $43,000 after purchasing an additional 32,922 shares during the period. CWM LLC boosted its stake in Neumora Therapeutics by 41.8% during the 2nd quarter. CWM LLC now owns 35,750 shares of the company’s stock valued at $26,000 after purchasing an additional 10,537 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at approximately $42,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.